Your browser doesn't support javascript.
loading
Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response.
Boziki, Marina; Bakirtzis, Christos; Sintila, Styliani-Aggeliki; Kesidou, Evangelia; Gounari, Evdoxia; Ioakimidou, Aliki; Tsavdaridou, Vasiliki; Skoura, Lemonia; Fylaktou, Asimina; Nikolaidou, Vasiliki; Stangou, Maria; Nikolaidis, Ioannis; Giantzi, Virginia; Karafoulidou, Eleni; Theotokis, Paschalis; Grigoriadis, Nikolaos.
Afiliação
  • Boziki M; Multiple Sclerosis Center of the 2nd Neurological University Department, School of Medicine, Aristotle University of Thessaloniki, AHEPA General University Hospital, 54636 Thessaloniki, Greece.
  • Bakirtzis C; Multiple Sclerosis Center of the 2nd Neurological University Department, School of Medicine, Aristotle University of Thessaloniki, AHEPA General University Hospital, 54636 Thessaloniki, Greece.
  • Sintila SA; Multiple Sclerosis Center of the 2nd Neurological University Department, School of Medicine, Aristotle University of Thessaloniki, AHEPA General University Hospital, 54636 Thessaloniki, Greece.
  • Kesidou E; Multiple Sclerosis Center of the 2nd Neurological University Department, School of Medicine, Aristotle University of Thessaloniki, AHEPA General University Hospital, 54636 Thessaloniki, Greece.
  • Gounari E; Microbiology Laboratory, Department of Immunology, AHEPA University Hospital, 54636 Thessaloniki, Greece.
  • Ioakimidou A; Microbiology Laboratory, Department of Immunology, AHEPA University Hospital, 54636 Thessaloniki, Greece.
  • Tsavdaridou V; Microbiology Laboratory, Department of Immunology, AHEPA University Hospital, 54636 Thessaloniki, Greece.
  • Skoura L; Microbiology Laboratory, Department of Immunology, AHEPA University Hospital, 54636 Thessaloniki, Greece.
  • Fylaktou A; National Peripheral Histocompatibility Center, Immunology Department, Hippokration General Hospital, 54642 Thessaloniki, Greece.
  • Nikolaidou V; National Peripheral Histocompatibility Center, Immunology Department, Hippokration General Hospital, 54642 Thessaloniki, Greece.
  • Stangou M; Department of Nephrology, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 54642 Thessaloniki, Greece.
  • Nikolaidis I; Multiple Sclerosis Center of the 2nd Neurological University Department, School of Medicine, Aristotle University of Thessaloniki, AHEPA General University Hospital, 54636 Thessaloniki, Greece.
  • Giantzi V; Multiple Sclerosis Center of the 2nd Neurological University Department, School of Medicine, Aristotle University of Thessaloniki, AHEPA General University Hospital, 54636 Thessaloniki, Greece.
  • Karafoulidou E; Multiple Sclerosis Center of the 2nd Neurological University Department, School of Medicine, Aristotle University of Thessaloniki, AHEPA General University Hospital, 54636 Thessaloniki, Greece.
  • Theotokis P; Multiple Sclerosis Center of the 2nd Neurological University Department, School of Medicine, Aristotle University of Thessaloniki, AHEPA General University Hospital, 54636 Thessaloniki, Greece.
  • Grigoriadis N; Multiple Sclerosis Center of the 2nd Neurological University Department, School of Medicine, Aristotle University of Thessaloniki, AHEPA General University Hospital, 54636 Thessaloniki, Greece.
Cells ; 11(12)2022 06 17.
Article em En | MEDLINE | ID: mdl-35741088
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Esclerose Múltipla Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article